At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiplatelets; Small molecules; Thrombolytics
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 09 Feb 1998 No-Development-Reported for Thrombosis in United Kingdom (Unknown route)
- 24 Oct 1994 Preclinical development for Thrombosis in United Kingdom (Unknown route)